Apowelis

Apowelis is a clinical-stage biotechnology company focused on developing oral small molecule inhibitors for chronic inflammatory and autoimmune diseases. The company's primary focus is on targeting the Interleukin-17 (IL-17) pathway, which is a validated driver of diseases such as psoriasis and psoriatic arthritis. Their lead candidate, APW-131, is designed as a potent and selective oral alternative to current injectable biologic therapies. By providing an oral treatment option, Apowelis aims to improve patient convenience and expand access to effective IL-17 inhibition. The company is led by a management team with extensive experience in drug development and commercialization within the immunology space. Apowelis is currently advancing its lead program through early-stage clinical trials to demonstrate safety and efficacy in patients with inflammatory conditions.